Long-term observation of patients successfully switched to risperidone long-acting injectable: A retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs

References

• Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, . Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting secondgeneration antipsychotic. J Clin Psychiatry 2003;64:1250–7.
   PubMed Web of Science ®Google Scholar
• Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004;19:241–9.
   PubMed Web of Science ®Google Scholar
• Leal A, Rosillon D, Mehnert A, Jarema M, Remington G. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf 2004;13:811–6.
   PubMed Web of Science ®Google Scholar
• Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004;19:219–25.
   PubMed Web of Science ®Google Scholar
• Kissling W, Heres S, Lloyd K, Sacchetti E, Bouhours P, Medori R, . Direct transition to long-acting risperidone-analysis of long-term efficacy. J Psychopharmacol 2005;19(Suppl 5):15–21.
   Google Scholar
• Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886–91.
   PubMed Web of Science ®Google Scholar
• Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry Suppl 1994;25:18–21.
   PubMedGoogle Scholar
• Joyce AT, Harrison DJ, Loebel AD, Ollendorf DA. Impact of atypical antipsychotics on outcomes of care in schizophrenia. Am J Manag Care 2005;11(Suppl 8):S254–61.
   Google Scholar
• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279–93.
   PubMed Web of Science ®Google Scholar
• Melchinger H, Machleidt W, Rössler W. Ausgaben auf dem Prüfstand. Dtsch Arztebl 2003;44:A2850–2.
   Google Scholar
• Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, . A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006;67:1194–1203.
   PubMed Web of Science ®Google Scholar
• Gaebel W, Bergmans P, de Arce R, Rouillon F, Cordes J, Eriksson L, . Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable versus quetiapline: Randomized, long-term, open- label, clinical trial results (ConstaTRE). Eur Psychiatry 2009;24 (Suppl 1): 1020.
   Google Scholar
• Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006;67:1948–53.
   PubMed Web of Science ®Google Scholar
• De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, . Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 2005;23(Suppl 1):35–47.
   Google Scholar
• Edwards NC, Locklear JC, Rupnow MF, Diamond RJ. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005;23(Suppl 1):75–89.
   PubMedGoogle Scholar
• Laux G, Heeg B, van Hout BA, Mehnert A. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005;23(Suppl 1):49–61.
   Google Scholar
• Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979;36(12):1283–94.
   Google Scholar
• Rote Liste Service GmbH (2007), Rote Liste 2007. Frankfurt am Main: n.s. (available from: http://www.rote-liste.de).
   Google Scholar
• Chue PS, Heeg B, Buskens E, van Hout BA. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005;23(Suppl 1):62–74.
   PubMedGoogle Scholar
• Niaz OS, Haddad PW. Thirty-five month experience of risperidone longacting injection in UK psychiatric service including a mirror-image analysis of inpatient care. Acta Psychiatr Scand 2007;116:36–46.
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A. on behalf of the e-STAR study group. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperi-done in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6(1):41–53.
   Google Scholar
• Chang HC, Tang CH, Tsai SJ, Yen FC, Su KP. Long-acting injectable risperidone and hospital readmission: a mirror-image study using a national claim-based database in Taiwan. J Clin Psychiatry 2009;70(1):141.
   Google Scholar
• Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 2006;114:14–20.
   PubMed Web of Science ®Google Scholar
• Taylor D, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand 2009:1–5. Epub 2009 Feb 3.
   Google Scholar
• Taylor M, Currie A, Lloyd K, Price M, Peperell K. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol 2008;22:128–31.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005;353:1209–23.
   PubMed Web of Science ®Google Scholar
• Hamann J, Langer B, Winkler V, Busch R, Cohen R, Leucht S, Kissling W. Shared decision making for in-patients with schizophrenia. Acta Psychiatr Scand 2006;114:265–73.
   PubMed Web of Science ®Google Scholar
• Kissling W, Vogel C. Brücken der Versorgung – Im Dreieck zwischen Arzt, Patient und Gesellschaft [Bridges of care – in the triangle between doctor, patient and society]. Neurotransmitter 2007;special edition 2:11–19.
   Google Scholar
• Rummel-Kluge C, Pitschel-Walz G, Kissling W. A fast implementable psychoeducation program for schizophrenia. Psychiatr Serv 2007;58:1226.
   PubMedGoogle Scholar
• Pitschel-Walz G, Bäuml J, Bender W, Engel RR, Wagner M, Kissling W. Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study. J Clin Psychiatry 2006;67:443–52.
   PubMed Web of Science ®Google Scholar
• Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients toward antipsychotic depot treatment. Int Clin Psychopharamacol 2007;22:275–92.
   PubMed Web of Science ®Google Scholar
• Salize HJ, Rössler W. Steigen die Versorgungskosten von Patienten mit Schizophrenie überproportional? [Is there a disproportional increase in health care costs for schizophrenic patients?]. Nervenarzt 1999;70:817–22.
   Google Scholar